Enovis (ENOV) Stock Overview
Operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
ENOV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Enovis Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$30.11 |
| 52 Week High | US$49.83 |
| 52 Week Low | US$29.13 |
| Beta | 1.83 |
| 1 Month Change | -4.59% |
| 3 Month Change | -24.73% |
| 1 Year Change | -33.22% |
| 3 Year Change | -48.32% |
| 5 Year Change | -61.77% |
| Change since IPO | -52.21% |
Recent News & Updates
New Product Pipeline Will Unlock International Orthopedic Markets
Successful product innovation and past acquisitions position Enovis for international market expansion and consistent revenue and earnings growth.Is Enovis (NYSE:ENOV) A Risky Investment?
May 09
Recent updates
New Product Pipeline Will Unlock International Orthopedic Markets
Successful product innovation and past acquisitions position Enovis for international market expansion and consistent revenue and earnings growth.Is Enovis (NYSE:ENOV) A Risky Investment?
May 09Enovis Corporation (NYSE:ENOV) Looks Inexpensive But Perhaps Not Attractive Enough
Apr 01Enovis (NYSE:ENOV) Has A Somewhat Strained Balance Sheet
Jan 20Enovis Corporation's (NYSE:ENOV) Shares Not Telling The Full Story
Dec 13Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt
Sep 24It's A Story Of Risk Vs Reward With Enovis Corporation (NYSE:ENOV)
Aug 20Enovis Languishing Despite Respectable Performance
Jul 15Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt
Jun 07Enovis: Solid Growth, But Unstable Financial Footing
May 05Enovis Corporation (NYSE:ENOV) Might Not Be As Mispriced As It Looks
Apr 22Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)
Feb 12Is Enovis (NYSE:ENOV) Using Too Much Debt?
Jan 14Investors Holding Back On Enovis Corporation (NYSE:ENOV)
Dec 18Calculating The Fair Value Of Enovis Corporation (NYSE:ENOV)
Nov 05Enovis Making Good Choices, But Not Seeing The Rewards
Sep 27Is Enovis (NYSE:ENOV) A Risky Investment?
Sep 22Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)
Aug 03Enovis Corporation: Things Are Looking Good As Guidance Is Raised
Jul 18We Think Enovis (NYSE:ENOV) Has A Fair Chunk Of Debt
Jun 20Enovis Corporation Q4 2022 Earnings Preview
Feb 22Is Enovis (NYSE:ENOV) A Risky Investment?
Feb 22Is Enovis Corporation (NYSE:ENOV) Worth US$60.5 Based On Its Intrinsic Value?
Jan 25Enovis Corporation reports Q3 earnings beat; updates FY22 guidance
Nov 02Is Enovis (NYSE:ENOV) A Risky Investment?
Oct 19Is Enovis Corporation (NYSE:ENOV) Trading At A 27% Discount?
Sep 14Enovis launches augmented reality system ARVIS for use in hip, knee surgery
Jul 19Here's Why Enovis (NYSE:ENOV) Can Manage Its Debt Responsibly
Jul 05Enovis announces CFO transition
Jun 30Shareholder Returns
| ENOV | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -5.6% | -0.7% | 0.0005% |
| 1Y | -33.2% | 5.5% | 10.0% |
Return vs Industry: ENOV underperformed the US Medical Equipment industry which returned 5.5% over the past year.
Return vs Market: ENOV underperformed the US Market which returned 10% over the past year.
Price Volatility
| ENOV volatility | |
|---|---|
| ENOV Average Weekly Movement | 7.7% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: ENOV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ENOV's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 7,367 | Damien McDonald | www.enovis.com |
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company’s Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals.
Enovis Corporation Fundamentals Summary
| ENOV fundamental statistics | |
|---|---|
| Market cap | US$1.72b |
| Earnings (TTM) | -US$811.94m |
| Revenue (TTM) | US$2.15b |
Is ENOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENOV income statement (TTM) | |
|---|---|
| Revenue | US$2.15b |
| Cost of Revenue | US$858.35m |
| Gross Profit | US$1.29b |
| Other Expenses | US$2.10b |
| Earnings | -US$811.94m |
Last Reported Earnings
Apr 04, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.21 |
| Gross Margin | 60.08% |
| Net Profit Margin | -37.76% |
| Debt/Equity Ratio | 53.0% |
How did ENOV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/22 15:30 |
| End of Day Share Price | 2025/06/20 00:00 |
| Earnings | 2025/04/04 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enovis Corporation is covered by 33 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Robert Cornell | Barclays |
| Christopher Williams | BB&T Capital Markets |